Zimmer grabs PA startup for cutting-edge knee treatment
Zimmer snatched up a Pennsylvania startup with a cutting-edge knee treatment surgical procedure, giving the medical device, implant and surgical product manufacturer a big boost to its own offerings in the space.
Life Tech's income slides as Thermo's wallet waits
Life Technologies is set to become part of Thermo Fisher come 2014, but for now, the company is still trying to balancing spiking costs and tepid revenue growth, watching profits slip 8.6% in the first quarter.
Dx to predict prostate cancer recurrence produces hopeful results
Prostate cancer treatment is in serious need of a diagnostic test that could better predict the chances it will recur. A new molecular diagnostics test designed to address this has generated some encouraging results in a study involving 270 tumor samples.
FDA panel rips Delcath drug/device cancer treatment
In what could be a deathblow for Delcath Systems, an FDA panel of experts voted unanimously that the risks of the company's drug-device combo to treat cancer outweighed any benefits.
Implant successfully predicts human epilepsy seizures
NeuroVista's implantable device successfully and correctly predicted epilepsy seizures in some adults for whom drugs haven't worked, a new proof-of-concept study found.
BioFire Diagnostics turns $25M financing into $45M cash infusion
BioFire Diagnostics has been able to transform $25 million financing first announced last fall into a much larger $45 million cash infusion, all to help the company quicken the commercialization and rollout of its molecular diagnostics platform.
Cardiovascular Systems' Q3 revenue grows
Cardiovascular Systems generated a big revenue jump in its fiscal 2013 third quarter, positive news as the company waits for the FDA's approval decision on its new device to treat calcified coronary arteries.
Study: Zinc may be ideal for bioabsorbable stents
Zinc may be the ideal ingredient for bioabsorbable stents, new research from Michigan Technology University concludes.
St. Jude targets FDA approval for next-gen CRT-D
St. Jude Medical is kicking off a large-scale study of its Quadripolar Pacing System, aiming for FDA approval for a device the company says could improve outcomes for patients who don't respond to standard treatment.
Smith & Nephew pursues emerging market M&A, plus $300M share buyback
Smith & Nephew is pursuing a massive share repurchasing program and continuing a quest for new acquisitions.
FDA slaps Class I on Covidien's ventilator battery recall
Last month, Covidien launched a recall of battery packs used with its Newport HT70 ventilators, and now the FDA has assigned its most serious designation to the problem, warning that the malfunctioning batteries could lead to injury or death.
Australian team advances Alzheimer's blood test work
Researchers at Australia's national science agency believe their effort to develop a blood test to detect early-stage Alzheimer's has reached a major milestone.
Allergan mulls suitors for obesity intervention unit
Allergan says it is mulling potential buyers for its obesity intervention unit and is on track to sell the division by mid-2013.
Hospira pulling the plug on troubled devices
After a year of recalls, bans and technical failures, Hospira is changing the way it does business in medical devices, planning to discontinue some of its infusion pumps and focus on next-generation technology.
Ex-Intuitive sales rep testifies: Surgical robot sales drove my pay
Testimony from an ex-Intuitive Surgical sales representative may have bolstered a lawsuit alleging the company marketed its signature surgical robots too aggressively, leaving out vital surgical training that led to a man's death.
Fresenius Medical watches profits slip amid U.S. struggles
Fresenius Medical, the world's largest dialysis company, posted a 39% profit drop last quarter, pulling in $225 million as its costs swelled.
Cardiovascular Systems addresses U.S. govt. info request in insider trader investigation
Medical device maker Cardiovascular Systems confirmed that the U.S. government has requested information as part of an investigation into corporate insider investment vehicles.
Let's not hold our breath for a device tax repeal
All the bipartisan agreement on repealing the medical device tax would suggest a short life for the 2.3% charge, but that's not quite how Washington works. Read more >>
Natera hauls in $54.6M for prenatal Dx
Natera is looking to bolster its share of the on-the-rise prenatal diagnostics market, raising $54.6 million in venture cash to expand the reach of its Panorama test.
St. Jude gains CE mark for quadripolar CRT pacer
St. Jude Medical ($STJ) scored European regulatory approval for a new quadripolar cardiac resynchronization therapy pacemaker. And with an immediate commercial rollout, the company gains another product that could help reverse sluggish revenue in the sector.
